Subject of class action lawsuit alleging false/misleading statements regarding TACTI-004 trial status and prospects between March 2025 and March 2026, suggesting misrepresentation of clinical trial information.
The company is accused of concealing negative clinical trial data, making false statements about trial progress, and misrepresenting the prospects of its TACTI-004 trial. These allegations of securities fraud and investor deception directly harm shareholder value and investor confidence.
The company is accused of concealing trial failure results and making false statements to investors about drug trial progress, resulting in shareholder losses and triggering a securities fraud lawsuit.
The company experienced an 83% single-day stock decline following disclosure that a Phase III clinical trial (TACTI-004) was discontinued for futility. This represents a significant adverse event that triggered investor losses and a securities class action lawsuit.
The company is accused of concealing material information about clinical trial risks while publicly stating the trial was on track. The subsequent trial discontinuation resulted in an 83% stock price decline, causing significant investor losses and triggering a class action lawsuit.
The company achieved positive Phase I interim results for its lead autoimmune candidate IMP761, meeting primary endpoints with favorable safety profile and statistically significant pharmacodynamic activity. The data supports advancement to Phase II and potential strategic collaborations, representing a significant clinical milestone for the company's pipeline.
Company is subject to securities class action lawsuit alleging false and misleading statements regarding clinical trial status and prospects, with claims that management concealed material risks of study failure despite public statements of 'strong operational progress.'
The company is accused of making false and misleading statements about a clinical trial (TACTI004) and concealing material information about the trial's failure risk. The lawsuit alleges defendants were aware of or reckless regarding negative internal data while publicly claiming the trial was on track, resulting in investor losses when the truth emerged.
The company is the subject of a securities class action lawsuit alleging material misrepresentations and concealment of negative clinical trial data. Defendants allegedly made false statements about trial progress while aware of internal data indicating increased risk of study failure, resulting in investor damages.
The company is the subject of a securities class action lawsuit alleging it made false and misleading statements about a clinical trial (TACTI004) and concealed material information about the trial's failure risk while publicly claiming strong operational progress. This represents significant legal and reputational risk to investors.
The company is the subject of a securities class action lawsuit alleging false and misleading statements about a clinical trial, indicating potential fraud and material misrepresentation that caused investor losses.
The company is accused of concealing material information about clinical trial risks while publicly stating strong progress. The subsequent trial discontinuation announcement resulted in an 83% stock price collapse, indicating severe investor harm and loss of confidence in company management and disclosures.
The company is the subject of a class action lawsuit alleging concealment and misrepresentation of clinical trial data. Defendants allegedly knew or were reckless regarding material risks that the TACTI-004 trial would fail to meet its primary endpoints, while publicly stating the trial was on track with strong operational progress. This represents significant legal and reputational risk to shareholders.
Company faces securities fraud lawsuit with 83% stock price collapse following failed Phase III clinical trial. Named executives allegedly made materially misleading statements about trial viability while possessing adverse internal data, exposing the company to significant legal and financial liability.
Company is accused of making false and misleading statements about the TACTI004 trial status and concealing material information about increased risk of study failure, resulting in investor damages.
The company is accused of concealing negative clinical trial data while publicly stating the trial was on track. The TACTI-004 Phase III trial was discontinued for futility, resulting in an 83% stock price decline and triggering a class action lawsuit for investor fraud.
The company announced discontinuation of a Phase III clinical trial for its lead candidate due to futility, resulting in an 82.6% stock price collapse. This represents a significant setback for the company's pipeline and investor value, triggering securities litigation.
The company received FDA Orphan Drug Designation for efti in soft tissue sarcoma, which provides regulatory advantages and market exclusivity. The Phase II trial demonstrated strong efficacy results (51.5% vs 35% target), supporting the therapeutic potential. However, sentiment is tempered by the recent discontinuation of the Phase III TACTI-004 trial due to futility analysis, indicating mixed clinical progress.
The company faces securities fraud investigation following a failed Phase III clinical trial announcement that caused an 82.44% stock price collapse. The trial discontinuation for futility represents a significant setback for the company's primary drug candidate and raises questions about potential prior misrepresentations to investors.
The company announced discontinuation of a Phase III clinical trial due to futility, resulting in an 82.6% stock price collapse. This represents a significant setback for the company's lead drug candidate and indicates potential material misrepresentation of business information to investors, triggering a securities class action investigation.
Articles that tag IMMP but are mainly about other companies.
Developing Eftilagimod Alfa, granted FDA Fast Track designation for first-line HNSCC treatment, positioning the company to benefit from the growing immunotherapy market.
Developing Eftilagimod Alfa, a novel LAG-3 agonist granted FDA Fast Track designation for first-line HNSCC treatment. The innovative mechanism of action positions the company well in the emerging immunotherapy landscape.
Company is under investigation for allegedly misleading investors regarding the viability and efficacy of its drug candidate, indicating potential securities fraud related to product development claims.
Company is subject to securities class action investigation by Rosen Law Firm, indicating alleged shareholder losses and potential securities violations.
The company is subject to a securities class action lawsuit involving American Depositary Receipts, indicating alleged investor harm and potential corporate misconduct, though specific details are not provided in the excerpt.
Company is subject to a securities class action lawsuit announced by Rosen Law Firm regarding American Depositary Receipts, indicating allegations of securities fraud or misconduct.
Company is defendant in securities class action lawsuit involving American Depositary Receipts, though specific allegations are not detailed in the provided excerpt.
Company is subject to securities investigation by Rosen Law Firm for allegedly issuing materially misleading business information to investors, indicating potential regulatory or disclosure issues.
Subject of securities investigation by Rosen Law Firm for allegedly issuing materially misleading business information to shareholders.
Rosen Law Firm is investigating potential securities claims on behalf of shareholders, indicating alleged securities violations or investor losses.
Subject of securities investigation by Johnson Fistel on behalf of investors, indicating potential securities law violations and investor losses.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
